Verici Dx PLC
Company Profile
Business description
Verici Dx PLC is an immuno-diagnostics development company. The company is focused on the development of prognostic and diagnostic tests for kidney transplant patients. There are two products for clinical validation and commercialization: Clarava, which is a pre-transplant prognosis for the risk of early acute rejection; Tuteva, a post-transplant diagnostic focused upon acute cellular rejection, including sub-clinical rejection not being diagnosed through the current standard of care of rising serum creatine levels; and Protega will utilize RNA gene signatures to more accurately risk stratify outcome from fibrosis in a transplant patient. The business of the Group comprises a single activity, which of the development of prognostic and diagnostic tests for kidney transplant patients.
Contact
19 Stanwell Road
Avon House
Penarth
CardiffCF64 2EZ
GBRT: +44 2920710570
Sector
Healthcare
Stock type
Defensive
Industry
Diagnostics & Research
Fiscal Year End
31 December 2025
Employees
23
Stocks News & Analysis
stocks
Fair value downgraded for ASX heavyweight
stocks
ChatGPT enters the retail space and one company surges
stocks
Alibaba fair value increases by 49%
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
---|---|---|---|
All Ordinaries | 9,136.60 | 15.10 | 0.17% |
CAC 40 | 7,964.00 | 68.06 | 0.86% |
DAX 40 | 24,083.24 | 202.52 | 0.85% |
Dow JONES (US) | 46,367.06 | 30.83 | -0.07% |
FTSE 100 | 9,436.80 | 86.37 | 0.92% |
HKSE | 26,855.56 | 232.68 | 0.87% |
NASDAQ | 22,641.22 | 18.79 | -0.08% |
Nikkei 225 | 44,550.85 | 381.78 | -0.85% |
NZX 50 Index | 13,433.99 | 141.63 | 1.07% |
S&P 500 | 6,679.87 | 8.59 | -0.13% |
S&P/ASX 200 | 8,845.70 | 12.30 | 0.14% |
SSE Composite Index | 3,882.78 | 20.25 | 0.52% |